Long-term pharmacologic treatment of atrial fibrillation underwent few changes in the years before the recent introduction of dronedarone. Use of this drug is restricted to patients with paroxysmal or persistent atrial fibrillation who are scheduled for electrical cardioversion and who show no signs of associated heart failure. The most important decision facing the cardiologist is still whether to attempt to maintain sinus rhythm or simply to maintain an adequate heart rate. The first option is preferred for symptomatic patients without substantial structural heart disease; the second is preferred for patients with no or few symptoms and those of advanced age who have associated structural heart disease which makes it unlikely that sinus rhythm can be maintained. The combination of pharmacologic treatment with nonpharmacologic treatment, such as ablation, is today a real option that will probably become more widely used in the near future.
|Translated title of the contribution||Long-Term Antiarrhythmic Drug Therapy for Atrial Fibrillation|
|Number of pages||6|
|Journal||Revista Espanola de Cardiologia Suplementos|
|Issue number||1 SUPPL.3|
|Publication status||Published - 2013|